[Form 3] Vistagen Therapeutics, Inc. Initial Statement of Beneficial Ownership

Rhea-AI Filing Summary

Vistagen Therapeutics (VTGN) has filed a Form 3 (Initial Statement of Beneficial Ownership) for Elissa S. Cote, who has been appointed as the company's Chief Corporate Development Officer. The filing date is June 28, 2025, with the triggering event occurring on June 23, 2025.

Key details from the filing:

• The reporting person currently owns no securities of the company, either direct or indirect
• No derivative securities (options, warrants, etc.) are reported as beneficially owned
• This is an individual filing, not a joint/group submission
• The filing address is listed as 343 Allerton Avenue, South San Francisco, CA 94080

This Form 3 filing is a standard regulatory requirement for new officers, directors, and 10% shareholders to disclose their initial ownership positions in the company's securities.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Cote Elissa S.

(Last) (First) (Middle)

C/O VISTAGEN THERAPEUTICS, INC.

343 ALLERTON AVENUE

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
06/23/2025

3. Issuer Name and Ticker or Trading Symbol
Vistagen Therapeutics, Inc. [ VTGN ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Corp Development Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ Elissa S. Cote	06/25/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Who is the new Chief Corporate Development Officer at VTGN (Vistagen Therapeutics)?

Elissa S. Cote was appointed as the Chief Corporate Development Officer at Vistagen Therapeutics (VTGN), as reported in a Form 3 filing dated June 28, 2025, following a triggering event on June 23, 2025.

Does VTGN's new Chief Corporate Development Officer Elissa Cote own any shares in the company?

According to the Form 3 filing, Elissa Cote does not beneficially own any securities of Vistagen Therapeutics (VTGN), either directly or indirectly, at the time of her appointment.

What is Elissa Cote's position at VTGN and when did she start?

Elissa Cote serves as Chief Corporate Development Officer at Vistagen Therapeutics (VTGN). Her appointment date requiring this Form 3 filing was June 23, 2025, as disclosed in the SEC filing.

Where is VTGN's new executive Elissa Cote based?

According to the Form 3 filing, Elissa Cote's business address is at Vistagen Therapeutics' location at 343 Allerton Avenue, South San Francisco, CA 94080.